One-stop Patient Support
Chiesi Total Care is a comprehensive support program for people impacted by rare diseases, their families, and their healthcare providers.
The program offers infusion support, coverage assistance, disease education, and access to a dedicated team that works together with one goal in mind: to support and simplify your treatment journey.*
For any treatment-related inquiries, Chiesi Total Care provides a team of Patient Service Managers and Patient Education Liaisons, via our toll-free line, to assist with any additional support needs throughout your treatment with Lamzede® (velmanase alfa-tycv).
Once your healthcare provider has made the independent decision to treat you with Lamzede, you can enroll into Chiesi Total Care by downloading and completing the Patient Enrollment and Consent Form below.
| * | Chiesi Total Care provides nonfinancial assistance to patients regardless of prescription drug coverage. Financial assistance is not available for those with government-funded insurance. Infusion assistance is not available for those receiving treatment or residing in MA or RI. Home infusion support requires a referral from your prescribing physician. Please see the full Terms and Conditions for additional eligibility requirements. |
Call toll free:
1-800-784-5840
Meet Your Chiesi Total Care Team:
Pharmacists
.png)
Nursing Support
Patient Service Managers (PSMs)†‡
Patient Education Liaisons (PELs)†‡
Field Reimbursement Managers (FRMs)†
| †PSMs, FRMs, and PELs are employees of Chiesi USA, Inc. ‡PSMs and PELs can be reached at 1-800-784-5840. |
The Chiesi Total Care Program Assists With:
Commercial insurance
If you have private insurance through your job or own your own business
Government insurance
If you have Medicare, Medicaid, Veterans Affairs healthcare, or other government insurance
No
insurance
If you have no insurance, you may be eligible for financial assistance
Infusion assistance§
- Ensures medication is delivered right to where you need it
- Assists you in finding an appropriate infusion facility
- Answers questions about administration, storage and disposal, and more
- Reviews eligibility for home infusion assistance§
| § | If you are receiving treatment or residing in MA or RI, you are not eligible for infusion assistance. To receive home infusion support, you must be referred to home infusion by your prescribing physician. Please see the full Terms and Conditions for additional eligibility requirements. |
For more information about Lamzede®, visit Lamzede.com.
Contact Information
Phone
Fax
Hours of operation
Monday to Friday
8:00 AM – 8:00 PM (Eastern Standard Time)
Location
One Boston Place, Suite 4030
Boston, MA 02108
Helpful Links
Below is a list of patient resources and organizations that can provide more information, support, or assistance with your care.
Please note: The information provided here reflects what is currently available and may be updated as new details emerge. Additional resources and options may also be available beyond those listed. This information is provided as a resource for you. Chiesi Total Care does not endorse or show preference for any foundation. Chiesi Total Care can only refer you to a foundation that supports your disease state. Independent financial assistance foundations have their own rules for eligibility. Chiesi USA does not fund independent financial assistance foundations, nor does Chiesi Total Care have involvement or influence in independent foundation decision making or eligibility criteria or know if a foundation will be able to help you.
Important Safety Information
What is the most important information I should know about Lamzede?
Severe allergic reactions (hypersensitivity reactions) including anaphylaxis, may occur during and after Lamzede treatment. If severe allergic reactions or anaphylaxis occur during treatment, your healthcare provider will immediately stop the infusion and provide appropriate medical care. If these reactions should occur after treatment, seek immediate medical care.
What should I know about infusions?
Your healthcare provider may give you other medications prior to your next infusion to help manage allergic reactions and infusion-related side effects. They will explain how to recognize the signs and symptoms of these allergic reactions and infusion-related side effects. If these signs and symptoms occur, it’s important for you to seek immediate medical care.
What are the common signs and symptoms of an allergic reaction or infusion-related side effects with Lamzede?
In clinical trials, some patients experienced signs and symptoms of an allergic reaction, which included bluish skin discoloration, low blood pressure, vomiting, hives, skin redness, facial swelling, fever, and involuntary movements.
In clinical trials, when patients experienced an infusion-related side effect, the most common signs were fever, chills, skin redness, vomiting, cough, itching, rash, and pink eye.
Are there certain people who should or should not take Lamzede?
Lamzede may cause harm to your unborn baby. For females who are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Lamzede. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. You should use effective birth control during treatment with Lamzede and for at least 14 days after the last dose.
What are the most common side effects of Lamzede?
Lamzede can cause side effects including severe allergic reactions and anaphylaxis, common cold, fever, headache, and joint pain or stiffness.
Please see full Prescribing Information for Lamzede.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Indication
Lamzede® (velmanase alfa-tycv) is intended for the treatment of non-central nervous system symptoms of alpha-mannosidosis in adult and pediatric patients.
Important Safety Information
What is the most important information I should know about Lamzede?
Severe allergic reactions (hypersensitivity reactions) including anaphylaxis, may occur during and after Lamzede treatment. If severe allergic reactions or anaphylaxis occur during treatment, your healthcare provider will immediately stop the infusion and provide appropriate medical care. If these reactions should occur after treatment, seek immediate medical care.
What should I know about infusions?
Your healthcare provider may give you other medications prior to your next infusion to help manage allergic reactions and infusion-related side effects. They will explain how to recognize the signs and symptoms of these allergic reactions and infusion-related side effects. If these signs and symptoms occur, it’s important for you to seek immediate medical care.
What are the common signs and symptoms of an allergic reaction or infusion-related side effects with Lamzede?
In clinical trials, some patients experienced signs and symptoms of an allergic reaction, which included bluish skin discoloration, low blood pressure, vomiting, hives, skin redness, facial swelling, fever, and involuntary movements.
In clinical trials, when patients experienced an infusion-related side effect, the most common signs were fever, chills, skin redness, vomiting, cough, itching, rash, and pink eye.
Are there certain people who should or should not take Lamzede?
Lamzede may cause harm to your unborn baby. For females who are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Lamzede. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. You should use effective birth control during treatment with Lamzede and for at least 14 days after the last dose.
What are the most common side effects of Lamzede?
Lamzede can cause side effects including severe allergic reactions and anaphylaxis, common cold, fever, headache, and joint pain or stiffness.
Please see full Prescribing Information for Lamzede.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Indication
Lamzede® (velmanase alfa-tycv) is intended for the treatment of non-central nervous system symptoms of alpha-mannosidosis in adult and pediatric patients.